Clinical trial NCT02099604: Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C
Official title: Efficacy and Safety of the Combination Vitamin D (Vit D), With Pegylated Interferon Alpha-2b (PEG-IFN)/Ribavirin (RBV) in Egyptian Patients With Untreated Chronic Hepatitis C: A Phase III Randomized Open-label Clinical Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Chronic Hepatitis C
Keywords: Hepatitis C - Genotype 4
SVR (Sustained Virological Response)
Vitamin D
Treatment Naïve
Lead sponsor: ANRS, Emerging Infectious Diseases
Sponsor class: OTHER_GOV
Collaborators: name: Institut Pasteur
First posted: 2014-03-31
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to show the superiority of a 4 weeks lead-in phase of Vitamin D followed by a 48 weeks combination of Vitamin D with PEG-IFN plus RBV in comparison with standard PEG-IFN + RBV in untreated Egyptian patients with chronic hepatitis C, on the sustained virological response (SVR) at 3 months after end of treatment (week 60).

Detailed description: - Method: Phase III, randomized, open-label superiority clinical trial, among Egyptian patients with chronic hepatitis C.

- Treatment strategy: Vitamin D Arm: Vitamin D over a 4 weeks lead-in phase followed by Vitamin D in combination with PEG-INF plus RBV during 48 weeks. Standard of Care Arm: PEG-INF plus RBV during 48 weeks.

- Main outcome: Proportion of patients with Sustained Virological Response (SVR) as defined by HCV RNA below the detection limit based on quantitative PCR 12 weeks after stopping treatment.

* Sample Size: 520 patients (260 per arm)
* Enrollment period: 12 months
* Patient's participation duration: 62 weeks (SOC Arm), 66 weeks (Vit-D Arm)
* Statistical analysis:

The superiority of the vitamin D arm will be tested against the standard PEG IFN + RBV combination. 260 patients in each arm will give 80% power to document a 12% difference in the SVR rates between the experimental (Vitamin D) and the control (standard treatment) arms..

A futility analysis is planned for this study, in order to be able to interrupt the trial prematurely in case preliminary results show a lack of efficacy of vitamin D.

This analysis will be performed on half of the patients, thus 260 patients (130 patients per arm), on a week 12/14 week criterion (HCV RNA viral load at W12/W14).

Eligibility criteria: Inclusion Criteria:

Common with National Program for Viral Hepatitis

* Age: 18 years to 60 years
* Positive HCV antibodies using a third generation test
* Detectable HCV RNA by PCR
* Liver biopsy showing chronic hepatitis with either a METAVIR score F1 with elevated liver enzymes or scores F2/F3
* Naïve to treatment with PEG-IFN and RBV
* HBs antigen negative
* Prothrombin time ≥60 %, normal bilirubin, alpha-foeto protein \< 3\*normal range of the laboratory, anti-nuclear antibodies\<1/160 Effective contraception during the treatment period; no breast-feeding

Specific to the trial

* Prior approval from the Ministry of Health to be treated as part of the National Program with allocation to Peg-IFN α2b treatment
* Living \<100 km from Cairo and able to come to the centre every week for the treatment
* Signed informed consent and willingness to participate in the trial
* Naïve to treatment with vitamin D (received vitamin D less than 30 consecutive days in the 3 months preceding inclusion)
* Biopsy slide validated by NHTMRI pathologist

Exclusion Criteria:

Common with National program for Viral Hepatitis

* Serious co-morbid conditions such as severe hypertension, heart failure, significant coronary heart disease, poorly controlled diabetes (HbA1C\>8%) , chronic obstructive pulmonary disease
* Major uncontrolled depressive illness
* Solid transplant organ (renal, heart, or lung)
* Untreated thyroid disease
* History of previous anti-HCV therapy
* Body mass index (BMI) greater than 30 kg/m²
* Known human immunodeficiency virus (HIV) coinfection: although HIV testing will not be proposed or done, patients with known HIV coinfection will not be included in the trial
* Anti-HCV therapy contraindications:
* hypersensitivity to one of the two drugs (PEG-IFN, RBV)
* pregnancy or unwilling to comply with adequate contraception
* breast-feeding
* neutropenia (\<1500/mm3)
* anaemia (\<11g/dL for women ; \<12g/dL for men)
* thrombocytopenia (\<100,000/mm3)
* elevated creatinin (\>1.5mg/dL)
* concomitant liver disease other than hepatitis C (immuno-active chronic hepatitis B, autoimmune hepatitis, alcoholic liver disease, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson disease)
* liver biopsy showing severe steatosis (\>66%) and steatohepatitis; decompensated cirrhosis (Child Pugh\>A); hepatocellular carcinoma, METAVIR score F4.
* TSH\>5 mU/L

Specific to the trial

* Patients allocated to Peg-IFN alpha 2a treatment
* Hypersensitivity to vitamin D
* Vitamin D contraindications:
* hypercalcaemia (fasting calcaemia \>105 mg/L or 2.62 mmol/L)
* ratio calciuria / creatininuria (fasting ratio \>1 mmol Ca/mmol creatinin)
* hyperphosphatemia (\>1.5 mmol/L)
* calcium lithiasis
* patients being treated with thiazide diuretics (risk of hypercalcaemia with vitamin D treatment)
* patients being treated with glucocorticoïds (decrease in vitamin D efficacy)
* postmenopausal women treated by vitamin D and calcium for osteoporosis
* Treatment by vitamin D more than 30 consecutive days in the 3 months preceding inclusion in the trial.

Primary outcomes:
measure: Proportion of patients with Sustained Virological Response (SVR).
timeFrame: 60 Weeks after peg-IFN/RBV initiation
Secondary outcomes:
measure: Rapid Virological Response (RVR)
timeFrame: 4 Weeks after peg-IFN/RBV initiation
measure: Early Virological Response (EVR)
timeFrame: 12 Weeks after peg-IFN/RBV initiation
measure: End of Treatment Response (ETR)
timeFrame: 48 Weeks after peg-IFN/RBV initiation
measure: Normalization of ALT during treatment and 12 weeks after the end of treatment
timeFrame: From 2 Weeks after peg-IFN/RBV initiation to End of Follow-up (Week 60)
measure: Incidence of serious adverse events (SAE) grade 3 and 4 (ANRS scale)
timeFrame: From Lead-in phase (Week -4) to End of Follow-up (Week 60)
measure: Evolution of FibroScan values between pre-inclusion and week 60
timeFrame: At Screening Visit 2 (S2) and at End of Follow-up (Week 60)
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: NHTMRI
Study officials:
affiliation: NHTMRI, Cairo, Egypt
name: Gamal Esmat, MD, PhD
role: STUDY_CHAIR
affiliation: Institut Pasteur, Paris France
name: Arnaud Fontanet, MD, PhD
role: STUDY_CHAIR
References: